BUDAPEST, Hungary, LONDON and PRINCETON, N.J., Oct. 6 /PRNewswire/ -- ThalesNano, Inc. today announced that it has signed agreements with a number of academic organizations including the Scripps Research Institute, the University of California, San Francisco, Boston University, Temple University and the University of Texas at Arlington. These institutions join the top 20 pharmaceutical companies, who have all deployed ThalesNano's H-Cube.
The H-Cube Hydrogenation Reactor is a bench-top standalone device, uniquely combining continuous-flow chemistry with endogenous hydrogen generation and a disposable catalyst cartridge system. At about a foot wide, and with the flexibility to use a vastly extended range of conditions compared to traditional techniques without any safety concerns, the H-Cube system is ideally suited to educational and to academic research laboratories.
Professor Phil Baran of the Scripps Research Institute explains, "The H-Cube has already had a dramatic effect on our research and that of several groups at Scripps. We believe the H-Cube will soon be as essential as an HPLC in the toolkit of a modern organic chemistry laboratory."
Added Dr. Chris O'Brien of the University of Texas at Arlington, "My group now take for granted that they can perform high pressure, high temperature hydrogenations with ease in a fume hood. To do these reactions conventionally requires substantial safety precautions and training. As testament to the H-Cube Midi's ease-of-use and scalability, high pressure hydrogenations are now routinely performed by undergraduates to yield 10s of grams of final product. H-Cube technology is a must-have for any synthetic laboratory."
"We believe that collaboration with leading universities will serve the entire chemistry community," said Dr. Laszlo Urge, CEO of ThalesNano, Inc. "These universities are teaching future generations about the alternative discovery methods and novel environmentally friendly technologies. We are delighted to work with these institutions who share our common vision of transforming the way that chemical entities are discovered. Their experience will further enhance the repertoire of published H-Cube reactions, which will provide great benefit to our community of academic and commercial users."
Dr. Ferenc Darvas, President and Chairman of ThalesNano, Inc. reflected, "The fact that our technology is seeing such wide acceptance in academia galvanizes H-Cube's position as the new paradigm for efficient hydrogenation. These schools are at the forefront in helping other academic institutions and the industry to realize the benefits of continuous flow technology in the future."
For more information please go to: http://www.thalesnano.com
About ThalesNano, Inc.:
ThalesNano is a world-leading provider of continuous process chemistry instruments in the rapidly developing market of laboratory and process scale flow reactors. The company has the widest portfolio of bench-top continuous process instruments. Its R&D 100 award winning H-Cube(R) continuous-flow hydrogenation reactor and the pilot plant scale version H-Cube Midi(TM) are used in hundreds of laboratories in four continents and have become the new industry standard for hydrogenation. 20 out of 20 of the largest pharmaceutical companies in the world employ ThalesNano products and technologies.
CONTACT: Laszlo Urge, Ph.D., CEO, ThalesNano, Inc., +36-1-880-8500,
Web site: http://www.thalesnano.com/